Ovarian germ cell tumors

Current Problems in Obstetrics, Gynecology and Fertility

Volumn 25, Issue 6, 2002, Pages 230-236

  Molina, Denise ^a   Hurteau, Jean ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; ETOPOSIDE; TUMOR MARKER;

ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CHORIOCARCINOMA; CLINICAL FEATURE; DYSGERMINOMA; EMBRYONAL CARCINOMA; FEMALE; GERM CELL TUMOR; HUMAN; LAPAROTOMY; OVARY CANCER; OVARY TERATOMA; SECOND LOOK SURGERY; YOLK SAC TUMOR;

EID: 0036869161     PISSN: 87560410     EISSN: None     Source Type: Journal    
DOI: 10.1067/mog.2002.130256     Document Type: Article

References (32)

1. Creasman WT, Soper JT. Assessment of the contemporary management of germ cell malignancies of the ovary. Am J Obstet Gynecol 1985;153:828-35.
2. Talerman A. Germ cell tumors of the ovary. In: Kurman RJ, editor. Blaustein's Pathology of the Female Tract. New York: Springer-Verlag; 1987. p. 659-721.
3. Krepart G, Smith JP, Rutledge F, Delclos L. The treatment for dysgerminoma of the ovary. Cancer 1978;41:986-990.
4. Kawai M, Kano T, Kikkawa F, Morikawa Y, Oguchi H, Nakashima N, et al. Seven tumor markers in benign and malignant germ cell tumors of the ovary. Gynecol Oncol 1992;45:248-253.
5. Zondag HA. Enzyme activity in dysgerminoma and seminoma: A study of lactic dehydrogenase isoenzymes in malignant diseases (the 1963 Fiske essay). R I Med J 1964;47:273-81.
6. Awais GM. Dysgerminoma and serum lactic dehydrogenase levels. Obstet Gynecol 1983;61:99-101.
7. Sheiko MC, Hart WR. Ovarian germinoma (dysgerminoma) with elevated serum lactic dehydrogenase: Case report and review of literature. Cancer 1983;49:994-8.
8. Schwartz PE, Morris JM. Serum lactic dehydrogenase: A tumor marker for dysgerminoma. Obstet Gynecol 1988;72:511-15.
9. Suzuki M, Kobayashi H, Ohwada M, Terao T, Sato I. Macrophage colony-stimulating factor as a marker for malignant germ cell tumors of the ovary. Gynecol Oncol 1998;68:35-7.
10. Kawata M, Sekiya S, Hatadeyama R, Takamizawa H. Neuron-specific enolase as a serum marker for immature teratoma and dysgerminoma. Gynecol Oncol 1989;32:191-7.
11. Altaras MM, Goldberg GL, Levin W, Darge L, Bloch B, Smith JA. The value of cancer antigen-125 as a tumor marker in malignant germ cell tumors of the ovary. Gynecol Oncol 1986;25:150-9.
12. Thomas GM, Dembo AJ, Hacker NF, DePetrillo AD. Current therapy for dysgerminoma of the ovary. Obstet Gynecol 1987;70:268-75.
13. Gershenson DM, Thomas GM, Dembo AJ, Hacker NF, DePetrillo AD. Update on malignant ovarian germ cell tumors. Cancer Suppl 1993;71:1581-90.
14. Slayton RE, Park RC, Silverberg SG, Shingleton H, Creasman WT, Blessing JA. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary: A Gynecologic Oncology Group study (a final report). Cancer 1985;56:243-248.
15. Williams SD, Blessing JA, Moore DH, Homesley HD, Adcock L. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ cell tumors. Ann Intern Med 1989;111:22-27.
16. Creasman WT, Fetter BF, Hammond CB, Parker RT. Germ cell malignancies of the ovary. Obstet Gynecol 1979;53:226-230.
17. Krepart G, Smith JP, Rutledge F, Delclos L. The treatment for dysgerminoma of the ovary. Cancer 1978;41:986-990.
18. Weinblatt ME, Ortega JA. Treatment of children with dysgerminoma of the ovary. Cancer 1982;49:2608-2611.
19. Jacobs AJ, Harris M, Deppe G, DasGupta I, Cohen CJ. Treatment of recurrent and persistent germ cell tumors with cisplatin, vinblastine, and bleomycin. Obstet Gynecol 1982;59:129-132.
20. Vriesendorp R, Aalders JG, Sleijfer DT, Willemse PHB, Bouma J, Mulder NH. Treatment of malignant germ cell tumors of the ovary with cisplatin, vinblastine, and bleomycin (PVB). Cancer Treat Rep 1984;68:779-781.
21. Williamse PHB, Aalders JG, Bouma J, Mulder NH, Verschueren RCJ, DeVries EGE, et al. Long-term survival after vinblastine, bleomycin and cisplatin treatment in patients with germ cell tumors of the ovary: An update. Gynecol Oncol 1987;28:268-277.
22. Williams SD, Blessing JA, Moore DH, Homesley HD, Adcock L. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ cell tumors. A trial of the Gynecologic Oncology Group. Ann Intern Med 1989;111:22-27.
23. Schwartz PE, Chambers SK, Chambers JT, Kohorn E, McIntosh S. Ovarian germ cell malignancies: The Yale University experience. Gynecol Oncol 1992;45:26-31.
24. Wu P, Huang R, Lang J, Huang HF, Lian LJ, Tang MY. Treatment of malignant ovarian germ cell tumors with preservation of fertility: A report of 28 cases. Gynecol Oncol 1991;40:2-6.
25. Gershenson DM, Wharton JT, Kline RC, Larson DM, Davanagh JJ, Rutledge FN. Chemotherapeutic complete remission in patients with metastatic ovarian dysgerminomas; potential for cure and preservation of reproductive capacity. Cancer 1986;58:2594-2599.
26. Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin (BEP). J Clin Oncol 1990;8:715-20.
27. Williams DS, Blessing JA, Hatch KD, Homesley HD. Chemotherapy of advanced dysgerminoma: Trials of the Gynecologic Oncology Group. J Clin Oncol 1991;9:1950-1955.
28. Marina NM, Cushing B, Giller R, Cohen L, Lauer SJ, Ablin A, et al. Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group intercrop study. J Clin Oncol 1999;17:2137-2143.
29. Dark CG, Bower M, Newlands ES, Paradinas F, Rustin GJS. Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol 1997;15:620-624.
30. Wangensteen OH, Lewis FJ, Tongen LA. The second look in cancer surgery. Lancet 1951;71:303.
31. Rutledge F, Burns B. Chemotherapy for advanced ovarian cancer. Am J Obstet Gynecol 1966;96:761-72.
32. Williams SD, Blessing JA, Di Saia PJ, Major FJ, Ball HG 3rd, Liao SY. Second look laparotomy in ovarian germ cell tumors: The Gynecologic Oncology Group experiences. Gynecol Oncol 1994;52:287-91.